Nanjing Zenshine Pharmaceuticals Co. Ltd. has disclosed fused heterocyclic compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.

Yingxi Intelligent Technology (Shanghai) Co. Ltd. has identified substituted monocyclic or bicyclic heterocyclic compounds acting as fibroblast growth factor receptor (FGFR) inhibitors and reported to be useful for the treatment of asthma, cancer, chronic heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, inflammation, autoimmune and Parkinson’s disease, among others.

Cannabidiol derivatives potentially useful for the treatment of Parkinson’s disease and epilepsy have been described in a Deyi Pharmaceutical Co. Ltd. patent.

Suzhou Puhe Biopharma Co. Ltd. researchers have prepared and tested substituted bicyclic heteroaryl compounds acting as GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.

Research at Vrise Therapeutics Inc. has led to the development of 5,6,7,8-tetrahydro-2,6-naphthyridine derivatives acting as GTPase KRAS (G12D mutant) inhibitors and thus reported to be useful for the treatment of cancer.

Helmholtz Zentrum Dresden Rossendorf has patented 3-((3-([1,1’-biphenyl]-3-ylmethoxy)phenoxy)methyl)benzonitrile derivatives that are radiolabeled compounds targeting programmed cell death 1 ligand 1 (PD-L1; CD274). They are reported to be potentially useful for the diagnosis and/or radionuclide therapy treatment of cancer and SARS-CoV-2.

Janssen Pharmaceutica NV has identified bicyclic pyridin-2-one and pyrimidin-4-one derivatives acting as coagulation factor XIa inhibitors and thus reported to be useful for the treatment of thromboembolism, diabetes, diabetic retinopathy, septic shock, hereditary angioedema, arthritis, nephropathy and inflammatory disorders, among others.

Gluetacs Therapeutics (Shanghai) Co. Ltd. has patented new proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a target protein binding moiety through a linker.

Researchers at Shanghai Institute of Materia Medica and the Wuhan Institute of Virology Chinese Academy of Sciences have prepared and tested cyclic bisbenzyl tetrahydroisoquinoline compounds reported to be useful for the treatment of fibrosis, viral infections and inflammatory disorders.

Daegu-Gyeongbuk Medical Innovation Foundation and Seoul National University Hospital have jointly developed adiponectin-derived peptoid derivatives reported to be useful for the treatment of skin inflammation, wound infection, alopecia, fibrosis, aging, skin wrinkling, cancer and metabolic diseases, among others.